{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:57.136196+00:00","company":{"ticker":"AMRX","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"7acfe694fc725d1c369c443a0c9c17d0ee25fa17","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.19","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$62 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$723 million"},"claim":"Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $723 million, net income $62 million, EPS $0.19. Guidance reaffirmed.","evidence_excerpt":"AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001723128-26-000019","anchor_url":"https://secwatch.observer/filing/0001723128-26-000019#claim-7acfe694fc725d1c369c443a0c9c17d0ee25fa17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/0001723128-26-000019-index.htm"},{"fact_type":"earnings_release","fact_key":"53314320bfe85b15d73b931c5e161dc4f849fc46","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-04-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-04-22","result_type":"preliminary_results","revenue_text":null},"claim":"Amneal Pharmaceuticals, Inc. updated its the first quarter ended March 31, 2026 guidance (raised).","evidence_excerpt":"On April 22, 2026, the Company issued a press release announcing its preliminary results for the first quarter ended March 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-168231","anchor_url":"https://secwatch.observer/filing/0001193125-26-168231#claim-53314320bfe85b15d73b931c5e161dc4f849fc46","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/0001193125-26-168231-index.htm"},{"fact_type":"material_agreement","fact_key":"f117823fd34a48fc81a124a8f24ac98b8848cf8e","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-04-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Membership Interest Purchase Agreement","agreement_type":"merger","counterparty":"Kashiv BioSciences, LLC","effective_date":"2026-04-21","item_codes_triggered":["1.01"],"value_text":"$375,000,000 in cash"},"claim":"Amneal Pharmaceuticals, Inc. entered into Membership Interest Purchase Agreement with Kashiv BioSciences, LLC valued at $375,000,000 in cash (effective 2026-04-21).","evidence_excerpt":"On April 21, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Amneal”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”), pursuant to which, among other matters and on the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to acquire from the Sellers 100% of the outstanding membership interests of Kashiv (the “Acquisition”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-168231","anchor_url":"https://secwatch.observer/filing/0001193125-26-168231#claim-f117823fd34a48fc81a124a8f24ac98b8848cf8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/0001193125-26-168231-index.htm"},{"fact_type":"debt_financing","fact_key":"b05248412bad0ee00a096398493d22d5685276ff","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-02-03T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2026-02-02","event":"incurrence","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"August 1, 2032","principal_text":"$134,673,472.50"},"claim":"Amneal Pharmaceuticals, Inc. incurred term loan of $134,673,472.50 with JPMorgan Chase Bank, N.A. maturing August 1, 2032.","evidence_excerpt":"the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the \"Additional Amendment No. 2 Term Loan\")","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-004738","anchor_url":"https://secwatch.observer/filing/0001628280-26-004738#claim-b05248412bad0ee00a096398493d22d5685276ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm"},{"fact_type":"debt_financing","fact_key":"2e0ccd6688aed4cf06943e1f491a38e3ec8336fd","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-02-03T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2026-02-02","event":"amendment","instrument_type":"credit_facility","interest_rate_text":"2.00% (for base rate) and 3.00% (for SOFR)","item_codes_triggered":["2.03"],"maturity_text":"August 1, 2032","principal_text":"$1,960,076,527.50"},"claim":"Amneal Pharmaceuticals, Inc. amended credit facility of $1,960,076,527.50 with JPMorgan Chase Bank, N.A. at 2.00% (for base rate) and 3.00% (for SOFR) maturing August 1, 2032.","evidence_excerpt":"on a cashless basis, its term loans outstanding immediately prior to the Repricing Amendment (the “Existing Term Loans) into new term loans with an aggregate principal amount of $1,960,076,527.50 (collectively, the “Converted Amendment No. 2 Term Loans”) and (y) the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the “Additional","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-004738","anchor_url":"https://secwatch.observer/filing/0001628280-26-004738#claim-2e0ccd6688aed4cf06943e1f491a38e3ec8336fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm"},{"fact_type":"material_agreement","fact_key":"04d03ebe50ac62376bc952795f09a77c9c882656","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-02-03T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 2 to Term Loan Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto","effective_date":"2026-02-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"Amneal Pharmaceuticals, Inc. amended Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto (effective 2026-02-02).","evidence_excerpt":"On February 2, 2026, Amneal Pharmaceuticals, Inc.’s (the \"Corporation\") subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Borrower”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the Repricing Amendment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-004738","anchor_url":"https://secwatch.observer/filing/0001628280-26-004738#claim-04d03ebe50ac62376bc952795f09a77c9c882656","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm"},{"fact_type":"debt_financing","fact_key":"1fe0cc6d2a5f258cabaab72fb34b17b4f505c121","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-08-01T23:59:59+00:00","payload":{"counterparty":"Wilmington Savings Fund Society, FSB, as trustee and collateral agent","effective_date":"2025-08-01","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"6.875%","item_codes_triggered":["2.03"],"maturity_text":"August 1, 2032","principal_text":"$600 million aggregate principal amount"},"claim":"Amneal Pharmaceuticals, Inc. incurred senior notes of $600 million aggregate principal amount with Wilmington Savings Fund Society, FSB, as trustee and collateral agent at 6.875% maturing August 1, 2032.","evidence_excerpt":"completed the previously announced offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Notes”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950103-25-009701","anchor_url":"https://secwatch.observer/filing/0000950103-25-009701#claim-1fe0cc6d2a5f258cabaab72fb34b17b4f505c121","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm"},{"fact_type":"debt_financing","fact_key":"dbeb505f778db447d23900139551809cba6aa10b","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-08-01T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A., as administrative agent","effective_date":"2025-08-01","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec","item_codes_triggered":["2.03"],"maturity_text":"August 1, 2032","principal_text":"$2.1 billion"},"claim":"Amneal Pharmaceuticals, Inc. incurred term loan of $2.1 billion with JPMorgan Chase Bank, N.A., as administrative agent at term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec maturing August 1, 2032.","evidence_excerpt":"On August 1, 2025, Amneal Pharmaceuticals, Inc.’s (the “Corporation”) subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Issuer”) borrowed $2.1 billion of new seven-year term B loans (the “New Term Loan”) pursuant to an amendment to the Company’s existing term loan credit facility","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950103-25-009701","anchor_url":"https://secwatch.observer/filing/0000950103-25-009701#claim-dbeb505f778db447d23900139551809cba6aa10b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm"},{"fact_type":"executive_change","fact_key":"9dc77bb596","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-03-06T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-01","interim":false,"role":"Executive Vice President, Chief Legal Officer & Corporate Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Jason Daly changed role as Executive Vice President, Chief Legal Officer & Corporate Secretary at Amneal Pharmaceuticals, Inc..","evidence_excerpt":"The Agreement provides that, as of the Effective Date, Mr. Daly will be employed as the Company’s Executive Vice President, Chief Legal Officer & Corporate Secretary at an annual base salary of $575,000.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001723128-25-000014","anchor_url":"https://secwatch.observer/filing/0001723128-25-000014#claim-9dc77bb596","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000014/0001723128-25-000014-index.htm"},{"fact_type":"shareholder_vote","fact_key":"277962e124eb6b4f1819d74a37dfe7243a280897","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-02","outcome":"passed","proposal_text":"To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"38,456","votes_against":"624,760","votes_for":"279,106,284","votes_withheld":null}]},"claim":"Amneal Pharmaceuticals, Inc. shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-02 meeting.","evidence_excerpt":"Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024: For Against Abstain Broker Non-Votes 279,106,284 624,760 38,456 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021107","anchor_url":"https://secwatch.observer/filing/0001628280-24-021107#claim-277962e124eb6b4f1819d74a37dfe7243a280897","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024021107/0001628280-24-021107-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e8d57777d1aaa6ba24bdb9c46b35721db7b405ad","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-02","outcome":"passed","proposal_text":"To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"24,065,209","subject":null,"votes_abstain":"139,222","votes_against":"1,199,935","votes_for":"254,365,134","votes_withheld":null}]},"claim":"Amneal Pharmaceuticals, Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2024-05-02 meeting.","evidence_excerpt":"Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 254,365,134 1,199,935 139,222 24,065,209","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021107","anchor_url":"https://secwatch.observer/filing/0001628280-24-021107#claim-e8d57777d1aaa6ba24bdb9c46b35721db7b405ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024021107/0001628280-24-021107-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8879667017bea3cb1225cc446d8052e951b037cd","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-02","outcome":"passed","proposal_text":"Election of director nominees to hold office until the 2025 Annual Meeting of Stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"24,065,209","subject":"Emily Peterson Alva","votes_abstain":"40,449","votes_against":null,"votes_for":"253,927,467","votes_withheld":"1,736,375"},{"broker_non_votes":"24,065,209","subject":"Deb Autor","votes_abstain":"40,288","votes_against":null,"votes_for":"254,054,265","votes_withheld":"1,609,738"},{"broker_non_votes":"24,065,209","subject":"J. Kevin Buchi","votes_abstain":"102,475","votes_against":null,"votes_for":"253,532,508","votes_withheld":"2,069,308"},{"broker_non_votes":"24,065,209","subject":"Jeff George","votes_abstain":"41,609","votes_against":null,"votes_for":"253,898,828","votes_withheld":"1,763,854"},{"broker_non_votes":"24,065,209","subject":"John Kiely","votes_abstain":"103,582","votes_against":null,"votes_for":"253,584,848","votes_withheld":"2,015,861"},{"broker_non_votes":"24,065,209","subject":"Paul Meister","votes_abstain":"42,130","votes_against":null,"votes_for":"238,720,752","votes_withheld":"16,941,409"},{"broker_non_votes":"24,065,209","subject":"Ted Nark","votes_abstain":"260,975","votes_against":null,"votes_for":"253,943,612","votes_withheld":"1,499,704"},{"broker_non_votes":"24,065,209","subject":"Chintu Patel","votes_abstain":"320,332","votes_against":null,"votes_for":"254,283,523","votes_withheld":"1,100,436"},{"broker_non_votes":"24,065,209","subject":"Chirag Patel","votes_abstain":"259,796","votes_against":null,"votes_for":"254,065,112","votes_withheld":"1,379,383"},{"broker_non_votes":"24,065,209","subject":"Gautam Patel","votes_abstain":"259,234","votes_against":null,"votes_for":"251,712,874","votes_withheld":"3,732,183"},{"broker_non_votes":"24,065,209","subject":"Shlomo Yanai","votes_abstain":"262,367","votes_against":null,"votes_for":"254,374,881","votes_withheld":"1,067,043"}]},"claim":"Amneal Pharmaceuticals, Inc. shareholders approved Election of director nominees to hold office until the 2025 Annual Meeting of Stockholders at the 2024-05-02 meeting.","evidence_excerpt":"Proposal 1 : To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 253,927,467 1,736,375 40,449 24,065,209","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021107","anchor_url":"https://secwatch.observer/filing/0001628280-24-021107#claim-8879667017bea3cb1225cc446d8052e951b037cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828024021107/0001628280-24-021107-index.htm"},{"fact_type":"earnings_release","fact_key":"abc42f280d646d38f368d310c8682f587b874fec","cik":1723128,"ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-05-03T23:59:59+00:00","payload":{"eps_text":"$0.30","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$92 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-03","result_type":"reported_results","revenue_text":"$659 million"},"claim":"Amneal Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $659 million, net income $92 million, EPS $0.30. Guidance reaffirmed.","evidence_excerpt":"the information furnished pursuant to Item 2.02 of this report. \n\n--- EX-99.1 (EX-99.1) ---\n\nAMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001723128-24-000018","anchor_url":"https://secwatch.observer/filing/0001723128-24-000018#claim-abc42f280d646d38f368d310c8682f587b874fec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/0001723128-24-000018-index.htm"}]}